Skip to main content
All lobbying filings

ALKERMES, INC.

Lobbying for ALKERMES, INC.

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 18, 2025
Expenses
$1,420,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Lobbying activity 3

Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Inflation Reduction Act of 2022 implementation, Part D redesign phase-in for small companies;

Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;

Expand funding and flexibility to address all substance use disorders;

 Bills named in this filing 4

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem